Boehringer Ingelheim’s adalimumab biosimilar Cyltezo approved in Europe

November 14, 2017 12:11 PM

boehringer-ingelheim-logo-biosimilarnews
Boehringer Ingelheim announced that the European Commission has granted marketing authorisation for Cyltezo a biosimilar to Humira for the treatment of multiple chronic inflammatory diseases in adults and children.

“Cyltezo is the first biosimilar from Boehringer Ingelheim approved in Europe, and marks a significant step forward for us in offering effective, and more affordable treatment options for patients with chronic inflammatory diseases,” said Ivan Blanarik, Senior Vice President and Head of Therapeutic Area Biosimilars at Boehringer Ingelheim. “Boehringer Ingelheim has been an industry leader in the production of biologics for 35 years, and we are delighted to have applied this expertise to the development of Cyltezo. We believe biosimilars will be a key contributor to the future sustainability of healthcare systems around the world.”

Cyltezo has been approved for the treatment of multiple chronic inflammatory diseases in adults, including:

  • Moderate to severely active rheumatoid arthritis
  • Psoriatic arthritis
  • Moderate to severely active Crohn’s disease
  • Severe active ankylosing spondylitis (AS)
  • Moderate to severely active ulcerative colitis
  • Severe axial spondyloarthritis without radiographic evidence of AS
  • Moderate to severe chronic plaque psoriasis
  • Moderate to severe hidradenitis suppurativa
  • Non-infectious intermediate, posterior and panuveitis.

Cyltezo has also been granted marketing authorisation for the treatment of paediatric inflammatory diseases, including moderate to severe Crohn’s disease (age six and older), severe chronic plaque psoriasis (age four and older), enthesitis-related arthritis (age six and older) and polyarticular juvenile idiopathic arthritis (age two and older).

The marketing authorisation of Cyltezo was based on a comprehensive data package supporting the biosimilarity of Cyltezo to Humira comprising analytical, pharmacological, non-clinical and clinical data.This included results from the pivotal Phase III study VOLTAIRE-RA, which demonstrated clinical equivalence in efficacy of BI 695501 to the reference product in patients with moderate to severely active rheumatoid arthritis by meeting its primary endpoint. Additionally the study showed no clinically meaningful differences between BI 695501 and Humira in terms of safety and immunogenicity.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Cyltezo on September 14th, 2017 and on August 25th, 2017, Cyltezo was approved by the U.S. Food and Drug Administration (FDA) in the United States (U.S.).

The product is not commercially available in Europe or the U.S. at this time. In any event Boehringer Ingelheim does not intend to launch Cyltezo in the EU before expiration of the respective SPC for adalimumab in October 2018. Boehringer Ingelheim is currently engaged in patent litigation with AbbVie in the U.S.

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!